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Abstract
Background: Dual antiplatelet therapy (DAPT) is recommended after elective percutaneous coronary 
intervention (PCI) in stable coronary artery disease (SCAD) patients; however, still one-third of patients 
do not obtain adequate platelet inhibition that may result in increased cardiovascular risk. The aim 
of the ONSIDE TEST study is to evaluate the clinical impact of point-of-care genotyping- and platelet 
function-based personalized dual antiplatelet strategies in SCAD individuals undergoing PCI. 
Methods: Fifty patients were randomized to one of the three study arms: 1) genotyping, 2) platelet 
function testing (PFT) and 3) control. Patients were tested with point-of-care Spartan RX CYP2C19 
System (group 1) and VerifyNow P2Y12 assay (group 2). In cases of inadequate response to clopidogrel, 
a loading dose of prasugrel was administered before PCI. The main clinical endpoint is the incidence 
of periprocedural myocardial injury (PMI). 
Results: Five (32%) patients in the genotyping arm and two (13%) in the in the PFT arm were identi-
fied as poor clopidogrel metabolizers. The periprocedural platelet reactivity was significantly lower in 
the genotyping (80 ± 49.0 PRU) and PFT (36.5 ± 47 PRU) arms as compared to the control arm  
(176 ± 67.8 PRU), p = 0.01 and p = 0.03, respectively. PMI appeared in 17 (37%) patients of the 
entire study population.
Conclusions: Personalized DAPT results in an improved platelet inhibition. Apart from genotyping 
and aggregometry, it is feasible to integrate into everyday clinical practice PMI rates which are relevant 
when comparing different strategies. (Cardiol J 2017; 24, 3: 284–292)
Key words: platelet aggregation inhibitors, platelet testing, clopidogrel, prasugrel,  
pharmacotherapy individualization
Introduction
Percutaneous coronary interventions (PCI) 
with the implantation of new-generation drug-
-eluting stents (DES) or bioresorbable scaffolds 
improves symptoms, reduces the risk for recurrent 
ischemic events and improves quality of life in pa-
tients with stable coronary artery disease (SCAD) 
[1–3] and verified ischemia. However, procedure-
related complications including stent thrombosis, 
distal embolization and vessel dissection still occur 
and may lead to peri-procedural myocardial injury 
or infarction with an elevation of cardiac enzymes 
(i.e. creatine kinase muscle-brain [CK-MB], car-
diac troponin T [cTnT] and I [cTnI]) in 20–30% of 
patients [4–6]. Dual antiplatelet therapy (DAPT) 
has proved to reduce these subsequent risks, al-
though the efficacy of the currently recommended 
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pharmacotherapy regime in SCAD, i.e. clopidogrel 
plus aspirin, is characterized by a large variability 
in the response of individual patients expressed 
by low platelet inhibition identified in 22–43% of 
the population [7–9]. By means of platelet function 
testing and genotyping, it is possible to identify 
patients who do not adequately respond to DAPT 
[10, 11]. In PCI patients treated with clopidogrel 
carriage of even one reduced-function CYP2C19 
allele (*2), there is an apparent association with 
a significantly increased risk of major adverse 
cardiovascular events (MACE), particularly stent 
thrombosis [11]. Hypothetically these individuals 
might be suitable candidates for more potent anti-
platelet agents (prasugrel, ticagrelor) that are char-
acterized by even stronger platelet inhibition and 
an ability to overcome high on-treatment platelet 
reactivity [12, 13]. The new generation rapid, easy-
to-use, point-of-care diagnostic testing-systems 
appear to be a promising solution with the potential 
to present advantages of advanced genotyping and 
platelet function testing (PFT) into everyday clini-
cal practice. To date, this personalized approach to 
periprocedural DAPT, although appealing, it has 
been difficult to implement in routine practice due 
to technical and logistic circumstances. In addition, 
results of previous large clinical trials focusing on 
hard clinical endpoints did not support the concept 
of individualization of antiplatelet therapy in low 
risk populations with SCAD. 
Nevertheless, the more potent P2Y12 inhibitors 
successful implementation into the clinical prac-
tice of PCI in an acute coronary syndrome setting 
remains vastly unexplored among patients under-
going elective PCI, and are also at risk of peripro-
cedural ischaemic complications. In the era of 
a wide access to the best-in-class DES it may be not 
feasible to conduct a study evaluating prasugrel or 
ticagrelor among stable angina subjects that would 
be powered for clinical endpoint. Thus, an approach 
to demonstrate the impact of antiplatelet therapy 
modification on myocardial injury expressed by 
biomarker leakage might constitute an efficient 
option to address this issue. 
Given this background, the ONSIDE TEST 
project was initiated (Optimal aNtiplatelet pharma-
cotherapy guided by bedSIDE genetic or functional 
TESTing in elective PCI patients) — an investi-
gator-initiated, phase IV, multicenter, prospective, 
open-label, randomized controlled clinical trial 
(NCT01930773), aimed to assess the efficacy of 
point-of-care genotyping and PFT in patients with 
SCAD undergoing elective PCI. In this pilot paper 
initial single-centre results of interim analysis 
of the first 50 patients was reported. This initial 
interim analysis was pre-specified to assess the 
feasibility of integrating the rapid point-of-care 
PFT and genotyping into the routine PCI practice, 
as well as to evaluate the safety of more potent 
antiplatelet drug administration among patients 
with stable angina. 
Methods
Selection of patients
The ONSIDE TEST Pilot study included pa-
tients treated at the Invasive Cardiology Unit of the 
1st Department of Cardiology, Medical University 
of Warsaw (Poland). Patients with stable coronary 
disease, between 18 and 75 years of age scheduled 
for an elective PCI with stent implantation were 
invited to participate in the study. The exclusion 
criteria comprised elevation of concentrations of 
myocardial necrosis enzyme at baseline, antici-
pated administration of glycoprotein IIb/IIIa inhibi-
tors, usage of rotational atherectomy, intervention 
in chronic total occlusion or bifurcation lesions, low 
platelet count (< 70,000/µL), high bleeding risk, 
coronary artery bypass surgery in last 3 months, 
severe chronic renal failure (estimated glomerular 
filtration rate < 30 mL/min), requirement for oral 
anticoagulation (warfarin, dabigatran, apixaban, 
rivaroxaban etc.), history of stroke or transient 
ischemic attack, weight < 60 kg, known bleed-
ing diathesis, hematocrit of < 30% or > 52% and 
pregnancy [14]. 
Financing and bioethics approval
The trial was sponsored by an independent 
research grant obtained from the Young Scientists 
Club 30 of the Polish Cardiac Society. The protocol 
was approved by the Bioethics Committee of the 
Medical University of Warsaw (Poland) in compli-
ance with the Declaration of Helsinki.
Endpoints
The primary efficacy outcome measure was 
the incidence of periprocedural myocardial injury 
defined as elevation of troponin I > 1 × 99th per-
centile upper limit of norm (ULN), but < 5 × 99th 
percentile ULN or elevation of troponin I > 5 × 
ULN in the absence of angiographic or imaging find-
ings of ischemia. The secondary outcome measures 
were maximum level of CK-MB elevation within 
24 h after PCI, maximum troponin elevation within 
24 h after PCI, the prevalence of periprocedural 
myocardial infarction, prevalence of periprocedural 
myocardial biomarker leak was understood as any 
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increase of myocardial necrotic enzymes above 
ULN. The periprocedural myocardial infarction 
was defined as troponin elevation 5 × > 99th per-
centile ULN and one of the following: 1) chest pain 
exceeding 20 min; 2) ischemic ST changes or new 
pathological Q waves; 3) angiographic evidence of 
flow limiting complication; or 4) imaging evidence 
of myocardial ischemia. The safety endpoints 
included the risk of Bleeding Academic Research 
Consortium (BARC)-defined type 3 (clinical, labo-
ratory, and/or imaging evidence of bleeding, with 
healthcare provider responses) and type 5 (fatal) 
bleeds happening within 7 and 30 days of PCI; and 
the rate of cardiac death, myocardial infarction, 
definite or probable stent thrombosis or urgent 
repeat revascularization within 30 days [15]. 
Study design
Patients who agreed to participate in the study 
and signed written informed consent were rand-
omized using an electronic randomization tool for 
iPhone [Randomizer for Clinical Trial, MEDSHAR-
ING, Fontenay Sous Bois, France] to three arms: 
1) phenotyping arm, 2) genotyping arm and 3) control 
arm [16]. All patients were on aspirin 75 mg daily 
and on clopidogrel 75 mg daily or received a load-
ing dose of clopidogrel 600 mg at least 6 h before 
testing. Patients in the phenotyping arm had their 
platelet reactivity checked using the point-of-care 
VerifyNow P2Y12 assay (Accumetrics, San Diego, 
US). Results were available within 5 min, values 
above the cutoff point of 208 platelet reactivity 
units (PRU) indicated inadequate platelet inhibi-
tion and a mandatory loading dose of prasugrel 
60 mg was administered followed by a daily dose of 
10 mg; other patients continued on clopidogrel. In the 
genotyping arm, the poor responders to clopidogrel 
were identified by the rapid, point-of-care Spartan 
RX CYP2C19 System (Spartan Bioscience Inc., 
Ottawa, Canada). Carriers of at least one copy of the 
CYP2C19*2 received a loading dose of prasugrel 
60 mg with a following 10 mg daily [14]. 
Statistical analysis
Statistical analysis was conducted using IBM 
SPSS Statistics, version 21.0 (IBM, New York). 
The statistical analysis was based on an intention-
to-treat population Shapiro-Wilk test which was 
used to check for normal distribution of continuous 
variables. Continuous variables were presented 
as mean ± one standard deviation (SD) or median 
depending on distribution. Groups were compared 
with t-Student or Mann-Whitney tests, respective-
ly. Nominal variables were shown as percentage or 
frequencies, and compared using the Fisher’s exact 
test. P-values lower than 0.05 were considered as 
statistically significant.
Results
Overall 50 patients, who were scheduled 
for an elective PCI with stent implantation were 
randomized between December 2012, and Novem-
ber 2014. Four patients had to be excluded from 
the final analysis: two received ticagrelor before 
platelet function testing and two withdrew the 
informed consent. This was a high-risk popula-
tion as per clinical characteristic with excessive 
prevalence of diabetes (39%), hypertension (70%), 
hyperlipidemia (70%), heart failure (37%), history 
of smoking (93%), or previous myocardial infarction 
(59%). Before admission most patients were on 
clopidogrel (76%) and all on aspirin. There were no 
significant differences in the baseline clinical char-
acteristics between the three study arms (Table 1).
The bedside testing was performed in all 
patients 8 ± 1.2 h before PCI. Genotyping took 
60 min and the test had to be repeated for 2 pa-
tients due to inconclusive results. The mean PFT 
time was 4 min. Nurses or physicians performed 
all tests and no input from trained laboratory staff 
was needed. 
The genotyping revealed that 15 (32.6%) pa-
tients had at least one copy of the loss-of-function 
(CYP2C19*2) allele, of those 2 (4.3%) were ho-
mozygous. At baseline, in the entire population the 
mean PRU was 157.5 ± 73.55, 11 (24%) patients 
had high on-treatment platelet reactivity accord-
ing to the prespecified cutoff value of PRU > 208 
(Table 2). Based on the point-of-care testing 5 (32%) 
patients in the genotyping arm and 2 (13%) patients 
in the PFT arm were identified as poor clopidogrel 
metabolizers and received loading dose of prasugrel 
at least 2 h before the scheduled PCI. No patient 
in the control arm was given prasugrel regardless 
of the geno-/phenotyping profile.
During the PCI most patients received 1 DES 
(83%) in left anterior descending artery (46%) 
(Table 3). Lesion preparation with predilatation 
was performed in 98% of cases; a balloon post-
dilatation was done in 1 of 5 patients. There were 
no major differences in terms of the procedural 
characteristics, except a numerically longer time 
of total vessel occlusion during intervention in the 
control group (Table 3). 
The periprocedural platelet reactivity was 
significantly lower in the genotyping (80 ± 49.0 
PRU) and phenotyping (36.5 ± 47.0 PRU) arms 
286 www.cardiologyjournal.org
Cardiology Journal 2017, Vol. 24, No. 3
Table 1. Baseline clinical characteristics.
Genotyping (n = 16) Aggregometry (n = 16) Control (n = 14)
Age [years] 61.2 ± 10.2 61 ± 6.54 63.5 ± 5.64
Female gender 7 (44%) 6 (38%) 5 (36%)
Height [cm] 170.5 ± 6.42 171.7 ± 9.35 170.9 ± 6.66
Weight [kg] 84.8 ± 13.41 87.1 ± 18.76 85.5 ± 16.14
Body mass index [kg/m2] 31.7 ± 5.92 28.4 ± 2.56 25.3 ± 3.36
Cardiac risk factors
Symptomatic stable CAD: 16 (100%) 11 (69%) 11 (79%)
CCS 1 5 (29.4%) 5 (35.7%) 7 (46.7%)
CCS 2 8 (47.1%) 4 (28.6%) 5 (33.3%)
CCS 3 4 (23.5%) 2 (14.3%) 0 (0%)
Hypertension 11 (69%) 10 (63%) 11 (79%)
Diabetes mellitus 7 (44%) 4 (25%) 7 (50%)
Hyperlipidemia 13 (82%) 10 (63%) 9 (65%)
Atrial fibrillation 1 (7%) 3 (19%) 3 (22%)
Heart failure (NYHA II–III) 5 (32%) 6 (38%) 6 (43%)
LVEF [%] 45 ± 16.9 44 ± 15.8 50 ± 11.7
COPD 1 (7%) 2 (13%) 2 (15%)
Smoking status 13 (82%) 16 (100%) 14 (100%)
Habitual smoker 4 (25%) 6 (38%) 4 (29%)
Ex-smoker 9 (57%) 10 (63%) 10 (72%)
Non-smoker 3 (19%) 0 (0%) 0 (0%)
Previous myocardial infarction 9 (57%) 11 (69%) 7 (50%)
Anterior wall 1 (7%) 5 (32%) 3 (22%)
Lateral wall 2 (13%) 1 (7%) 0 (0%)
Inferior wall 5 (32%) 5 (32%) 3 (22%)
Posterior wall 1 (7%) 0 (0%) 1 (8%)
Previous PCI 9 (57%) 9 (57%) 7 (50%)
Laboratory
CK-MB [ng/mL] 0.60 (0.35–1.25) 1.05 (0.62–1.97) 1.60 (0.65–2.65)
Troponin I [ng/mL] 0.002 (0.000–0.009) 0.007 (0.000–0.019) 0.014 (0.000–0.022)
Creatinine [mg/dL] 0.9 ± 0.20 1.0 ± 0.20 1.0 ± 0.32
eGFR [mL/min/1.73 m2] 57 (49–59) 59 (51–60) 58 (51–60)
Red blood cells [106/µL] 4.6 ± 0.35 4.7 ± 0.51 4.8 ± 0384
Hamoglobin [g/dL] 14.5 ± 0.97 14.6 ± 1.22 14.2 ± 1.14
Platelets [103/µL] 241 ± 68.9 245 ± 79.8 219 ± 80.3
INR 1.00 ± 0.069 1.00 ± 0.055 0.98 ± 0.055
APTT [s] 27 ± 2.2 32 ± 3.7 29 ± 2.4
AST [U/L] 21.5 ± 5.92 23.9 ± 6.54 24.8 ± 7.52
ALT [U/L] 29.7 ± 11.67 33.1 ± 12.95 45.62 ± 67.126
Baseline pharmacotherapy
Aspirin 16 (100%) 13 (82%) 14 (100%)
Clopidogrel 14 (88%) 12 (75%) 9 (65%)
Statin 16 (100%) 13 (82%) 13 (93%)
Beta-blocker 16 (100%) 12 (75%) 12 (86%)
ACE-I or ARB 15 (94%) 12 (75%) 12 (86%)
Calcium channel blocker 1 (7%) 1 (7%) 0 (0%)
Proton pump inhibitor 5 (32%) 8 (50%) 7 (50%)
Data are presented as count and percentage (%) or mean ± standard deviation; CAD — coronary artery disease; CCS — Canadian Cardio-
vascular Society; NYHA — New York Heart Association; LVEF — left ventricular ejection fraction; COPD — chronic obstructive pulmonary 
disease; PCI — percutaneous coronary intervention; CK-MB — creatine kinase muscle-brain; eGFR — estimated glomerular filtration rate;  
INR — international normalized ratio; APTT — activated partial thromboplastin time; AST — aspartate aminotransferase; ALT — alanine  
aminotransferase; ACE-I — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker
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as compared to the control arm (176 ± 67.8 PRU), 
(p = 0.01 and p = 0.03, respectively). 
The periprocedural myocardial injury appeared 
in 17 (37%) patients of the entire study population. 
There were no statistically significant differences 
in terms of the periprocedural myocardial injury in 
the control, aggregometry and genotyping groups 
(35.7%, 37.5%, and 40%, respectively, p = 0.97) 
(Table 4). The median peak CK-MB elevation with-
in 24 h after PCI was 2.0 ng/mL. Seven patients in 
the control arm, 9 in the phenotyping arm and 5 in 
the genotyping arm had CK-MB above the median. 
Table 2. Platelet function, genotype and pharmacotherapy.
Genotyping  
(n = 16)
Aggregometry  
(n = 16)
Control  
(n = 14)
Before testing
Baseline pharmacokinetic response, platelet reactivity [PRU] 160.5 ± 61.36 138.4 ± 87.7 177.5 ± 67.8
High platelet reactivity, PRU > 208 2 (13%) 5 (32%) 4 (29%)
CYP2C19*2 carrier (heterozygote) 5 (32%) 4 (25%) 4 (29%)
CYP2C19 carrier (homozygote) 1 (7%) 0 (0%) 1 (8%)
After testing
Switch to prasugrel 5 (32%) 2 (13%) 0 (0%)
Data are presented as count and percentage (%) or mean ± standard deviation; PRU — platelet reactivity units
Table 3. Procedural characteristics.
Genotyping  
(n = 16)
Aggregometry  
(n = 16)
Control  
(n = 14)
Lesion location
Left main 0 (0%) 1 (7%) 0 (0%)
Left anterior descending artery 7 (44%) 8 (50%) 6 (43%)
Circumflex artery 3 (19%) 2 (13%) 4 (29%)
Right coronary artery 3 (19%) 3 (19%) 1 (8%)
Number of stents
One 11 (69%) 12 (75%) 11 (79%)
Two 5 (32%) 4 (25%) 3 (22%)
Drug eluting stent 14 (88%) 13 (82%) 11 (79%)
Bare metal stent 2 (13%) 3 (19%) 3 (22%)
Direct stenting 0 (0%) 1 (7%) 0 (0%)
Stent postdilatation 3 (19%) 3 (19%) 3 (22%)
Total length of stent [mm] 27.1 ±13.79 26.1 ±14.01 28.8 ±23.18
Total vessel occlusion time [s] 79 ± 40.1 102 ± 53.6# 68 ± 23.4#
Periprocedural pain 1 (7%) 1 (7%) 1 (8%)
Intravascular ultrasound 1 (7%) 1 (7%) 0 (0%)
Optical coherence tomography 1 (7%) 1 (7%) 0 (0%)
Periprocedural pharmacotherapy
Unfractionated heparin [103 units] 6.9 ± 2.34 8.1 ± 1.94) 8.0 ± 1.73
Abciximab 1 (7%) 0 (0%) 0 (0%)
Eptifibatide 1 (7%) 0 (0%) 0 (0%)
Good angiographic result (TIMI 3) 15 (94%) 16 (100%) 13 (93%)
Data are presented as count and percentage (%) or mean ± standard deviation; #p = 0.066
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The median peak troponin elevation within 24 h 
was 0.19 ng/mL. Seven patients in the control arm, 
8 in the phenotyping arm and 8 in the genotyping 
arm had CK-MB above the median. There were 
no differences in the prevalence of periprocedural 
myocardial infarction, myocardial biomarker leak, 
and risk of major bleeding and MACE at the 30-day 
follow-up. Main study outcomes are presented in 
Table 4.
Discussion
In research of the literature, this is the first 
study aiming to compare two point-of-care testing 
methods in a head-to-head manner with standard 
care in patients undergoing elective PCI for SCAD. 
The present report confirmed safety and feasibility 
of personalized point-of-care strategy in this patient 
population. Previous studies have assessed only 
one type point-of-care testing and did not evalu-
ate the platelet inhibition before and during PCI. 
It is worth underlining that the presented results 
are based on one third of the planned population 
and should be examined carefully. In the present 
study no differences were found in terms of peak 
CK-MB within 24 h after PCI between the three 
study populations. There are no other studies that 
would assess the myocardial injury in relation to 
type of antiplatelet drug used. However there is 
evidence that higher platelet reactivity during PCI 
is related to periprocedural myonecrosis [17] and 
worse prognosis [18–25].
There was a significantly stronger platelet inhibi-
tion in the genotyping and PFT groups as expressed 
by the PRU values than in the control group. This is 
in line with pharmacodynamic data from the Testing 
platelet Reactivity In patients undergoing elective 
stent placement on clopidogrel to Guide alternative 
thErapy with pRasugrel (TRIGGER PCI) study that 
demonstrated the efficacy of prasugrel in overcoming 
HTPR on clopidogrel in patients with SCAD [12].
The number of heterozygous carriers of the 
CYP2C19*2 allele observed in this study confirms 
the observations from previous studies [11, 26–28]. 
It should be noted that in the genotyping group 
there was a numerically higher rate of periproce-
dural myocardial injury than in the control group. 
Nevertheless, it was mainly driven by procedural 
mechanical complications (severe artery dissec-
tion) and thus, cannot be directly associated with 
inadequate response to antiplatelet agents.
The data from randomized clinical trials con-
firmed that stronger platelet inhibition in acute 
coronary syndrome patients treated with PCI re-
duces the rate of ischemic events, with an increase 
in risk of bleeding complications [29–32]. However, 
such an association has been less apparent in pa-
tients with stable angina [33].
Dual antiplatelet tailored strategy based on 
bedside aggregometry was previously studied 
Table 4. Main study outcomes.
Genotyping  
(n = 16)
Aggregometry  
(n = 16)
Control  
(n = 14)
P: Gen  
vs. Agg*
P: Agg  
vs. Con*
P: Gen  
vs. Con*
Pharmacokinetic response  
30 min after PCI [PRU]
80.3 ± 49 36.5 ± 47 177.5 ± 67.8 0.39 0.01 0.03
Periprocedural myocardial injury 40.0% 37.5% 35.7% 1.00 1.00 1.00
Peak CK-MB elevation [ng/mL] 1.3 (0.7–4.2) 2.4 (1.1–4.1) 2.1 (1.1–3.5) 0.82 0.72 0.85
Periprocedural MI [cTnI > 5 × 
ULN + symptoms]
6.3% 0.0% 0.0% 0.31 1.00 0.34
Periprocedural myocardial  
biomarker leak [cTnI or  
CK-MB > 1 × ULN]
80.0% 81.3% 75.0% 1.00 1.00 1.00
Peak TnI elevation [ng/mL] 1.73  
(0.41–3.16)
1.92  
(0.82–5.99)
1.54   
(0.54–5.00)
0.33 0.36 0.32
BARC 3 or 5 bleeding  
(within 7 days)
0.0% 12.5% 0.0% 0.16 0.17 1.00
Cardiac death, MI, stent  
thrombosis, revascularization 
(within 30 days)
6.3% 0.0% 0.0% 0.31 1.00 0.34
Data are presented as count and percentage (%), median and interquartile range or mean ± standard deviation; Agg — aggregometry;  
Gen — genotyping; PCI — percutaneous coronary intervention; PRU — platelet reactivity units; CK-MB — creatine kinase muscle-brain;  
MI — myocardial infarction; cTnI — cardiac troponin I; ULN — upper normal limit; BARC — Bleeding Academic Research Consortium
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by Collet et al. [34], however in the Assessment 
by a Double Randomization of a Conventional 
Antiplatelet Strategy versus a Monitoring-guided 
Strategy for Drug-Eluting Stent Implantation and 
of Treatment Interruption versus Continuation 
One Year after Stenting (ARCTIC) trial pre-PCI 
intensification of P2Y12 and glycoprotein IIb/IIIa 
inhibition when monitoring with VerifyNow P2Y12 
aggregometry revealed a poor response to clopi-
dogrel did not show any improvement in ischemic 
or safety outcomes with a strategy of monitoring 
and drug adjustment as compared with a con-
ventional treatment strategy [34]. Similarly, the 
TRIGGER PCI study, comparing prasugrel vs. 
clopidogrel in the low risk population of patients 
screened with the VerifyNow assay after elective 
uncomplicated angioplasty with DES implantation 
was stopped prematurely for futility [12]. In the 
group of 236 patients with complete 6-month fol-
low-up only one primary endpoint of cardiac death 
or myocardial infarction had occurred, accounting 
for an incidence of 0.4%. As the rate of MACE in 
the population of SCAD patients is minimal in the 
era of new generation DES, it might not be feasible 
to perform an appropriately sized study assessing 
clinical endpoints with sufficient statistical power. 
Having evidence for a gradual increase in mortal-
ity risk with each increment of CK-MB plasma 
concentration after PCI [35–37], it appears that 
an approach involving assessment of surrogate 
endpoint (i.e. myocardial injury) might be more 
efficacious in verification of tailored antiplatelet 
therapy hypothesis in low-risk populations. Nev-
ertheless, the threshold beyond which biomarker 
elevations are clinically significant still needs to 
be determined, presumably with the employment 
of high-resolution imaging to verify the extent of 
myonecrosis [38, 39]. The plasma levels of myo-
cardial injury biomarkers were comparable in all 
three-study arms in this study. However, the study 
is still ongoing and will continue until 362 subjects 
are randomized, according to the already reported 
sample size analyses.
Notably, the present investigation provided 
also novel data on the prevalence of periprocedural 
myocardial infarction in the elective PCI patient 
population, that might also constitute additional 
reference for other investigators, as the evidence 
on the incidence of periprocedural myocardial 
injury among SCAD patients undergoing invasive 
treatment remains unsatisfactory. 
Finally, in this pilot study, it was also confirmed 
that the feasibility and convenience of point-of-care 
testing methods in the assessment of response to 
antiplatelet therapy in patients undergoing elec-
tive PCI. Both phenotyping and genotyping could 
have been performed by a physician or nurse sub-
sequent to a short training and the results could 
have been achieved quickly, especially in cases of 
aggregometry. 
Limitations of the study
The main limitation of this study is a small 
number of enrolled patients. Another limitation is 
a potential lack of sensitivity of the primary end 
point, which may be driven by the incidence of 
periprocedural technical complications apart from 
adequate platelet inhibition. However, the approach 
enclosing exclusion of periprocedural myocardial 
infarction from the study endpoint analysis has al-
ready proved to be ineffective [12] and the optimal 
antiplatelet therapy might potentially attenuate 
ischemic complications of PCI. Furthermore, 
a limitation of this trial is also its open-label design, 
which was the consequence of numerous interven-
tions occurring over the course of this study. 
Conclusions
In the present study, individualization of an-
tiplatelet therapy on the basis of point-of-care 
platelet function testing by switching to prasugrel 
in SCAD patients with high on-clopidogrel plate-
let reactivity resulted in a consistent decrease 
in platelet reactivity, achieving a level similar to 
that observed in clopidogrel responsive subjects. 
This pilot study confirms feasibility of bedside 
genotyping and phenotyping testing in everyday 
clinical practice. 
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